Correction to: Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines [Biotechnol. J. 9 (2014)] doi: 10.1002/biot.201300225;Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines

Biotechnology Journal

Volumn 9, Issue 3, 2014, Pages 405-414

  Nakowitsch, Sabine ^a   Waltenberger, Andrea M ^a   Wressnigg, Nina ^a   Ferstl, Nicole ^a   Triendl, Andrea ^a   Kiefmann, Bettina ^a   Montomoli, Emanuele ^b   Lapini, Giulia ^b   Sergeeva, Maria ^c   Muster, Thomas ^a   Romanova, Julia R ^a,c  

^a Avir Green Hills Biotechnology AG   (Austria)

^b UNIVERSITY OF SIENA   (Italy)

^c Research Institute of Influenza   (Russian Federation)

Author keywords

Hemagglutinin antigen content; Inactivated vaccines; Influenza virus; PH stability; Temperature stability

Indexed keywords

ANTIGENS; CELL CULTURE; CELLS; PH EFFECTS; STABILITY; SUBSTRATES; VACCINES;

ACIDIFIED CONDITIONS; CONFORMATIONAL CHANGE; ELEVATED TEMPERATURE; HEMAGGLUTININ ANTIGEN CONTENT; INFLUENZA VACCINES; INFLUENZA VIRUS; PH STABILITY; TEMPERATURE STABILITY;

VIRUSES;

HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE;

ACIDITY; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CONCENTRATION (PARAMETERS); CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG QUALITY; EGG DERIVED SEED VIRUS; HIGH TEMPERATURE; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MDCK CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PH; PHENOTYPE; PRIORITY JOURNAL; PURIFICATION; STORAGE; VERO CELL; VIROGENESIS; VIRUS CULTURE; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS TITRATION;

ORTHOMYXOVIRIDAE;

HEMAGGLUTININ ANTIGEN CONTENT; INACTIVATED VACCINES; INFLUENZA VIRUS; PH STABILITY; TEMPERATURE STABILITY;

ANIMALS; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MUTATION; VACCINES, INACTIVATED; VERO CELLS;

EID: 84897609583     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201490012     Document Type: Erratum

References (34)

1. Lu, B., Zhou, H., Ye, D., Kemble, G. et al., Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. J. Virol. 2005, 79, 6763-6771.
2. Masuda, H., Suzuki, T., Sugiyama, Y., Horiike, G. et al., Substitution of amino acid residue in influenza A virus hemagglutinin affects recognition of sialyl-oligosaccharides containing N-glycolylneuraminic acid. FEBS Lett. 1999, 464, 71-74.
3. Saito, T., Nakaya, Y., Suzuki, T., Ito, R. et al., Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation. J. Med. Virol. 2004, 74, 336-343.
4. Chen, Z., Zhou, H., Jin, H., The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine 2010, 28, 4079-4085.
5. Doroshenko, A., Halperin, S. A., Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert. Rev. Vaccines. 2009, 8, 679-688.
6. Ehrlich, H. J., Muller, M., Oh, H. M., Tambyah, P. A. et al., A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 2008, 358, 2573-2584.
7. Nakowitsch, S., Wolschek, M., Morokutti, A., Ruthsatz, T. et al., Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1. Vaccine 2011, 29, 3517-3524.
8. Reed, L. J., Muench, H., A simple method of estimating fifty per cent endpoints. Am. J. Hygiene. 1938, 493-497.
9. Mostow, S. R., Schild, G. C., Dowdle, W. R., Wood, R. J., Application of the single radial diffusion test for assay of antibody to influenza type A viruses. J. Clin. Microbiol. 1975, 2, 531-540.
10. Bullough, P. A., Hughson, F. M., Skehel, J. J., Wiley, D. C., Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994, 371, 37-43.
11. Daniels, R. S., Downie, J. C., Hay, A. J., Knossow, M. et al., Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell 1985, 40, 431-439.
12. Rachakonda, P. S., Veit, M., Korte, T., Ludwig, K. et al., The relevance of salt bridges for the stability of the influenza virus hemagglutinin. FASEB J. 2007, 21, 995-1002.
13. Vanderlinden, E., Goktas, F., Cesur, Z., Froeyen, M. et al., Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J. Virol. 2010, 84, 4277-4288.
14. Krenn, B. M., Egorov, A., Romanovskaya-Romanko, E., Wolschek, M. et al., Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS. One. 2011, 6, e18577.
15. Daniels, P. S., Jeffries, S., Yates, P., Schild, G. C. et al., The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. EMBO J. 1987, 6, 1459-1465.
16. Skehel, J. J., Wiley, D. C., Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69, 531-569.
17. Harvey, R., Martin, A. C., Zambon, M., Barclay, W. S., Restrictions to the adaptation of influenza a virus h5 hemagglutinin to the human host. J. Virol. 2004, 78, 502-507.
18. Mitnaul, L. J., Matrosovich, M. N., Castrucci, M. R., Tuzikov, A. B. et al., Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J. Virol. 2000, 74, 6015-6020.
19. Stevens, J., Blixt, O., Glaser, L., Taubenberger, J. K. et al., Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J. Mol. Biol. 2006, 355, 1143-1155.
20. Falchi, A., Varesi, L., Arena, C., Leveque, N. et al., Co-circulation of two genetically distinct sub-groups of A/H3N2 influenza strains during the 2006-2007 epidemic season in Corsica Island, France. J. Clin. Virol. 2009, 45, 265-268.
21. Chen, Z., Zhou, H., Jin, H., The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine 2010, 28, 4079-4085.
22. Huang, Q., Opitz, R., Knapp, E. W., Herrmann, A., Protonation and stability of the globular domain of influenza virus hemagglutinin. Biophys. J. 2002, 82, 1050-1058.
23. Chou, P. Y., Fasman, G. D., Empirical predictions of protein conformation. Annu. Rev. Biochem. 1978, 47, 251-276.
24. Martin, J., Wharton, S. A., Lin, Y. P., Takemoto, D. K. et al., Studies of the binding properties of influenza hemagglutinin receptor-site mutants. Virology 1998, 241, 101-111.
25. Busch, M. G., Bateman, A. C., Landolt, G. A., Karasin, A. I. et al., Identification of amino acids in the HA of H3 influenza viruses that determine infectivity levels in primary swine respiratory epithelial cells. Virus Res. 2008, 133, 269-279.
26. Amorij, J. P., Huckriede, A., Wilschut, J., Frijlink, H. W. et al., Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 2008, 25, 1256-1273.
27. Carr, C. M., Chaudhry, C., Kim, P. S., Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 14306-14313.
28. Imai, M., Watanabe, T., Hatta, M., Das, S. C. et al., Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012, 486, 420-428.
29. Weldon, W. C., Wang, B. Z., Martin, M. P., Koutsonanos, D. G. et al., Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS. One. 2010, 5, e12466.
30. Babiuk, S., Skowronski, D. M., De Serres, G., HayGlass, K. et al., Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model. J. Med. Virol. 2004, 72, 138-142.
31. De Serres, G., Boulianne, N., Duval, B., Rochette, L. et al., Oculo-respiratory syndrome following influenza vaccination: evidence for occurrence with more than one influenza vaccine. Vaccine 2003, 21, 2346-2353.
32. Murakami, S., Horimoto, T., Ito, M., Takano, R. et al., Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion. J. Virol. 2012, 86, 1405-1410.
33. Kelley, L. A., Sternberg, M. J., Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc. 2009, 4, 363-371.
34. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S. et al., UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605-1612.